Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug r...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Chinês |
| Argitaratua: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-09-01
|
| Saila: | Chinese Journal of Lung Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|